Linagliptine Eg (Eurogenerics) Sa

Linagliptin, the active ingredient in Linagliptine Eg, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control and is indicated for patients who need additional therapy beyond diet and exercise.

GNH USA supplies Linagliptine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality‑assurance procedures and provides full regulatory documentation to support global distribution and ensures timely delivery.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves blood glucose control when added to diet, exercise and other antidiabetic agents. Renal impairment: provides effective glycemic control without the need for dose adjustment. Elderly patients: offers once‑daily oral therapy with a low risk of hypoglycemia.

Linagliptin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Dizziness: sensation of light‑headedness. - Gastrointestinal discomfort: nausea, diarrhea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation. - Severe allergic reactions: angioedema, urticaria or anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing linagliptin, clinicians should consider several safety aspects.

Renal impairment: no dose adjustment required but monitor renal function regularly. Hepatic impairment: use with caution and assess liver enzymes. Hypersensitivity: discontinue immediately if signs of allergic reaction appear. Pancreatitis: advise patients to report persistent abdominal pain promptly. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Linagliptin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure and effectiveness. - Combination with insulin or sulfonylureas: increases risk of hypoglycemia. - Concurrent use with strong P‑glycoprotein inhibitors: may elevate linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Diuretics: assess for dehydration and electrolyte imbalance. - Anticoagulants (warfarin): observe INR for potential changes.